Dr Reddys Laboratories schedules board meeting to approve Q2 FY2026 unaudited results
The board will meet on 22 July 2026 to consider and approve the standalone and consolidated financial results for the quarter ended 30 June 2026.
What Dr Reddys Laboratories announced
Dr Reddys Laboratories Ltd informed the Bombay Stock Exchange (BSE) that its Board of Directors will convene on 22 July 2026. The agenda includes the consideration and approval of the unaudited standalone and consolidated financial results for the quarter ending 30 June 2026. The intimation was filed on 22 June 2026 at 11:26 UTC.
Board meeting details
The notice specifies that the meeting will be held in accordance with the provisions of the Companies Act, 2013 and the company’s Articles of Association. While the filing does not disclose the venue, it confirms that the meeting will be attended by the entire board, and the results will be presented for approval before they are made public.
Financial results to be considered
The filing references the unaudited financial statements for both the standalone entity and the consolidated group. No quantitative data—such as revenue, profit, or margin figures—are provided in the notice. The company typically releases the detailed numbers after board approval, at which point they become available to shareholders and the market.
Key facts at a glance
| Detail | Value |
|---|---|
| Company | Dr Reddys Laboratories Ltd |
| BSE Code | 500124 |
| Board meeting date | 22 July 2026 |
| Filing date | 22 June 2026 (11:26 UTC) |
| Subject of meeting | Approval of unaudited Q2 FY2026 results |
| Financial period covered | Quarter ending 30 June 2026 |
| Source | BSE filing (PDF) |
Why this matters for investors
The board’s approval is a prerequisite for the company to publish its quarterly performance. Investors rely on the unaudited results to gauge short‑term trends in sales, profitability, and cash flow before the audited figures are released. The timing also signals the company’s commitment to regulatory compliance, as the board must formally endorse the numbers before they can be disseminated to the market.
Conclusion
Dr Reddys Laboratories has formally announced a board meeting on 22 July 2026 to approve its unaudited Q2 FY2026 financial results. The filing does not contain any financial metrics; those will be disclosed after the board’s consideration. Stakeholders should watch for the subsequent release of the results, which will provide insight into the company’s operational performance for the quarter.
Frequently asked questions
Related stocks
Source filing: view original